Showing results (2171-2180 of 2,378) with videos related to

Sort By:
Pageof 238
Science Advances|July 27, 2022
Chaperoning of the histone octamer by the acidic domain of DNA repair factor APLFIvan Corbeski, Xiaohu Guo, Bruna V Eckhardt, et al.
Kidney International Reports|March 20, 2023
Early Ultrastructural Changes in Biopsies From Patients With Symptomatic CKD of Uncertain EtiologyChristoph Daniel, Philipp Enghard, Neelakanthi Ratnatunga, et al.
Nature Communications|July 30, 2026
Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trialValentina O Puntmann, Eike Nagel, Dietrich Beitzke, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapyYalda Amidi, Christine A Eckhardt, Syed A Quadri, et al.
Journal of Animal Science|May 10, 2013
Differences in maternal plane of nutrition and body condition during late gestation coupled with estrus synchronization at weaning do not result in differences in embryonic development at 4 days of gestationO H O Eckhardt, F C Horta, L J Parazzi, et al.
International Journal of Molecular Sciences|March 29, 2023
Adipose-Derived Stem Cells in Reinforced Collagen Gel: A Comparison between Two Approaches to Differentiation towards Smooth Muscle CellsElena Filova, Monika Supova, Adam Eckhardt, et al.
Cancers|October 13, 2021
A Multi-Scale and Multi-Technique Approach for the Characterization of the Effects of Spatially Fractionated X-ray Radiation Therapies in a Preclinical ModelMariele Romano, Alberto Bravin, Alberto Mittone, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)Ilaria Colombo, Kira-Lee Koster, Lisa Holer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumorsDavid S Hong, Daniel W Bowles, Gerald S Falchook, et al.
Investigational New Drugs|October 27, 2016
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)Kit Man Wong, Lindsey N Micel, Heather M Selby, et al.
Pageof 238